title: [Palivizumab: four seasons in Russia].
abstract: In 2010, the Russian Federation (RF) registered palivizumab--innovative drug, based on monoclonal antibodies for passive immunization of seasonal respiratory syncytial virus (RSV) infection in children of disease severe progress risk group, which include primarily premature infants, children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease. Currently, palivizumab is included in the list of recommended medicines and medical care standards of different countries, including Russia. In the review the results of Russian research on the progress of RSV infection, its epidemiology and immunization experience gained over the 2010-2014 period are summarized in relation to the foreign data. During the four epidemic seasons palivizumab immunization covered more than 3,200 children of severe RSV infection risk group with a progressive annual increase in the number of patients who received the drug. Geography of palivizumab immunization is also greatly expanded in our country during this time. If during the first two seasons measures of immunization were taken mainly in Moscow and St. Petersburg, at the present time, thirty one territorial entities of the Russian Federation have the experience in the drug application. Analysis of the results of RSV infection immunization (made in several regions) confirms the high clinical efficacy and palivizumab safety already demonstrated in international studies. In addition, the analysis presents the potential to improve the efficiency of the integrated RSV infection immunization programs, realizing in the establishment of high-risk child group register, adequate counseling for parents, as well as the development of the routing of patients and coordination of interaction between different health institutions during the immunization.
authors.forename: A A
authors.initials: AA
authors.lastname: Baranov
authors.forename: D O
authors.initials: DO
authors.lastname: Ivanov
authors.forename: G A
authors.initials: GA
authors.lastname: Aliamovskaia
authors.forename: V R
authors.initials: VR
authors.lastname: Amirova
authors.forename: I V
authors.initials: IV
authors.lastname: Antoniuk
authors.forename: G A
authors.initials: GA
authors.lastname: Asmolova
authors.forename: I A
authors.initials: IA
authors.lastname: Beliaeva
authors.forename: E L
authors.initials: EL
authors.lastname: Bokeria
authors.forename: O A
authors.initials: OA
authors.lastname: Briukhanova
authors.forename: I V
authors.initials: IV
authors.lastname: Vinogradova
authors.forename: E V
authors.initials: EV
authors.lastname: Vlasova
authors.forename: A N
authors.initials: AN
authors.lastname: Galustian
authors.forename: G V
authors.initials: GV
authors.lastname: Gafarova
authors.forename: V V
authors.initials: VV
authors.lastname: Gorev
authors.forename: I V
authors.initials: IV
authors.lastname: Davydova
authors.forename: D N
authors.initials: DN
authors.lastname: Degtiarev
authors.forename: E A
authors.initials: EA
authors.lastname: Degtiareva
authors.forename: V V
authors.initials: VV
authors.lastname: Dolgikh
authors.forename: I M
authors.initials: IM
authors.lastname: Donits
authors.forename: N I
authors.initials: NI
authors.lastname: Zakharova
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Zernova
authors.forename: E P
authors.initials: EP
authors.lastname: Zimina
authors.forename: V V
authors.initials: VV
authors.lastname: Zuev
authors.forename: E S
authors.initials: ES
authors.lastname: Keshishian
authors.forename: I A
authors.initials: IA
authors.lastname: Kovalev
authors.forename: I E
authors.initials: IE
authors.lastname: Koltunov
authors.forename: A A
authors.initials: AA
authors.lastname: Korsunskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Krivoshchekov
authors.forename: I V
authors.initials: IV
authors.lastname: Krsheminskaia
authors.forename: S N
authors.initials: SN
authors.lastname: Kuznetsova
authors.forename: V A
authors.initials: VA
authors.lastname: Liubimenko
authors.forename: L S
authors.initials: LS
authors.lastname: Namazova-Baranova
authors.forename: É V
authors.initials: ÉV
authors.lastname: Nesterenko
authors.forename: S V
authors.initials: SV
authors.lastname: Nikolaev
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Ovsiannikov
authors.forename: T I
authors.initials: TI
authors.lastname: Pavlova
authors.forename: M V
authors.initials: MV
authors.lastname: Potapova
authors.forename: L V
authors.initials: LV
authors.lastname: Rychkova
authors.forename: A A
authors.initials: AA
authors.lastname: Safarov
authors.forename: A I
authors.initials: AI
authors.lastname: Safina
authors.forename: M A
authors.initials: MA
authors.lastname: Skachkova
authors.forename: I G
authors.initials: IG
authors.lastname: Soldatova
authors.forename: T V
authors.initials: TV
authors.lastname: Turti
authors.forename: N A
authors.initials: NA
authors.lastname: Filatova
authors.forename: R M
authors.initials: RM
authors.lastname: Shakirova
authors.forename: O S
authors.initials: OS
authors.lastname: Ianulevich
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage; D001997:Bronchopulmonary Dysplasia / Q000453:epidemiology; D005260:Female; D006330:Heart Defects, Congenital / Q000453:epidemiology; D006801:Humans; D017589:Immunization Programs / Q000379:methods / Q000458:organization & administration; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D008297:Male; D000069455:Palivizumab; D015397:Program Evaluation / Q000706:statistics & numerical data; D012042:Registries; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology / Q000517:prevention & control; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab